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Glioblastoma   is   the   most   common   and   malignant   subtype   of   glioma,   exhibiting   remarkable   resistance   to  
treatment.  Here  we  investigated  the  oncogenic  potential  of  HOXA9  in  gliomagenesis,  the  molecular  and  cellular  
mechanisms  by  which  HOXA9  may  render  glioblastoma  more  aggressive,  and  how  HOXA9  affects  response  to  
chemotherapy   and   prognosis.   Expression   microarrays   were   used   to   identify   HOXA9   target   genes.   Stable  
glioblastoma   cell   lines   with   ectopic   HOXA9   overexpression   or   shRNA-­‐mediated   knockdown   of   HOXA9   were  
established   to   evaluate   the   roles  of  HOXA9   in   cell   viability,   death,   invasion,   and   response   to   temozolomide.  
Subcutaneous  and  orthotopic   intracranial  xenograft  models  of  glioblastoma  were  established  to  evaluate  the  
oncogenic   potential   of   HOXA9   in   vivo,   and   its   role   in   response   to   temozolomide   and   overall   survival.  
Transcriptomic  analyses   identified  novel  HOXA9-­‐target  genes  that  have  key  roles   in  critical  cancer  processes,  
including   cell   proliferation,   adhesion,   DNA   metabolism   and   repair,   and   stem   cell   maintenance.   Functional  
assays  with  a  variety  of  glioblastoma  cells  revealed  that  HOXA9  promotes  cell  viability,  stemness,  and  invasion;  
conversely,  HOXA9  displayed  anti-­‐apoptotic  functions.  Additionally,  ectopic  expression  of  HOXA9  promoted  the  
malignant   transformation   of   human   immortalized   astrocytes   in   an   intracranial   orthotopic   mouse   model   of  
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glioblastoma,   and   caused   tumor-­‐associated   death.   HOXA9   also   mediated   resistance   to   temozolomide  
treatment  both  in  vitro  and  in  vivo.  Mechanistically,  BCL2  was  identified  as  a  novel  HOXA9  target  that  may  be  
therapeutically   targeted.   Indeed,   the   pharmacological   inhibition   of   BCL2   with   ABT-­‐737   specifically   reverted  
temozolomide   resistance   in   HOXA9-­‐positive   cells.   These   data   establish   HOXA9   as   a   critical   driver   of   glioma  
initiation,  aggressiveness  and  resistance  to  therapy.    
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